Preparation for 131 I remnant ablation with 54 mCi is equally effective with thyroid hormone withdrawal and recombinant human TSH

JUNE 2009 18 VOLUME 21  ISSUE 6 Back to

[1]  E. Baudin,et al.  Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. , 2009, The Journal of clinical endocrinology and metabolism.

[2]  M. Schott.  Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008 .

[3]  E. Mazzaferri.  Management of low-risk differentiated thyroid cancer. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  I. Hay.  Management of patients with low-risk papillary thyroid carcinoma. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[5]  T. Pilli,et al.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  A. Driedger,et al.  Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. , 2006, Thyroid : official journal of the American Thyroid Association.

[7]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[8]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[9]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  G. Mariani,et al.  Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. , 2003, The Journal of clinical endocrinology and metabolism.

[11]  A. Pinchera,et al.  Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.

[12]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[13]  M. Ringel,et al.  Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  S. Larson,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. , 2001, Thyroid : official journal of the American Thyroid Association.

[15]  A. Pinchera,et al.  Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. , 2001, European journal of endocrinology.

[16]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[17]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[18]  E. Kaplan,et al.  Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.